Abemaciclib and Letrozole to Treat Endometrial Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

October 10, 2020

Primary Completion Date

December 1, 2024

Study Completion Date

December 1, 2025

Conditions
Endometrial Cancer
Interventions
DRUG

Abemaciclib

Abemaciclib 150mg orally twice a day

DRUG

Letrozole

Letrozole 2.5mg orally once a day

Trial Locations (29)

10032

Columbia University Medical Center, New York

13210

SUNY Upstate Medical University, Syracuse

19090

Abington Memorial Hospital, Willow Grove

19611

Reading Hospital-McGlinn Cancer Institute, Reading

22908

University of Virginia, Charlottesville

26506

West Virginia University, Morgantown

31405

Lewis Cancer & Research Pavilion, Savannah

32160

UF Health Cancer Center, Gainesville

32804

Advent Health - Orlando, Orlando

33136

University of Miami - Sylvester Cancer Center, Miami

UT Health Tower, Miami

33146

Sylvester Comprehensive Cancer Center-Lennar Foundation Medical Center, Coral Gables

33324

Sylvester Comprehensive Cancer Center-Plantation, Plantation

33331

Cleveland Clinic Florida, Weston

33442

Sylevester Comprehensive Cancer Center-Deerfield Beach, Deerfield Beach

36604

University of South Alabama Mitchell Cancer Center, Mobile

40503

Baptist Healthcare System, Lexington

48106

St. Joseph Mercy Hospital, Ann Arbor

60637

University of Chicago, Chicago

74146

Oklahoma Cancer Specialists and Research Institute, Tulsa

84112

Baptist Health Center Lexington, Salt Lake City

Huntsman Cancer Institute, Salt Lake City

99508

Alaska Women's Cancer Care, Anchorage

06830

Smillow Cancer Care at Greenwich, Greenwich

06520

Yale University, New Haven

02111

Tufts Medical Center, Boston

01605

University of Massachusetts, Worcester

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

07666

Holy Name Medical Center, Teaneck

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Gynecologic Oncology Group

NETWORK